- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHINA YONGXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 33,920 | -0,21 % | H.C. Wainwright bestätigt Kaufempfehlung für Ionis Pharmaceuticals-Aktie bei 50 US-Dollar | ||
| CSPC PHARMA | 0,851 | +0,76 % | CSPC PHARMA (01093): NOMINATION COMMITTEE - TERMS OF REFERENCE | ||
| SELLAS LIFE SCIENCES | 1,722 | +4,11 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
| ACADIA PHARMACEUTICALS | 18,560 | -1,75 % | Acadia's 'very bullish' sales forecast restores some confidence on Wall Street | ||
| MADRIGAL PHARMACEUTICALS | 258,90 | +0,74 % | Madrigal, Viking among notable gainers after Altimmune's MASH setback | ||
| CATALYST PHARMACEUTICALS | 18,450 | -0,86 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,080 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,845 | +0,48 % | Opus Genetics, Inc.: Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025 | Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 1,930 | +2,66 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,060 | +0,98 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,856 | -2,23 % | Biodexa Pharmaceuticals PLC: Results of Annual General Meeting | June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,593 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 10-Q, Quarterly Report |
CHINA YONGXIN PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA YONGXIN PHARMACEUTICALS INC finden Sie auf Wallstreet Online.